PA-CLINICAL-INK
17.11.2021 18:19:07 CET | Business Wire | Press release
Clinical Ink today announced it ranked on the Deloitte Technology Fast 500 ™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th year. Clinical Ink grew 293% during this period.
Clinical Ink’s Chief Executive Officer, Ed Seguine , credits the 293% growth to expertise in highly complex therapeutic areas (Alzheimer's, Lupus, COVID) and novel execution models such as decentralized and remote trials. Seguine stated, “Clinical Ink has consistently delivered results for our customers and earned their trust. We’ve always been at the forefront of innovation with technologies that simplify and accelerate complex clinical trial activities. The recent acquisition of Digital Artefacts will drive future growth as we lead the next wave of innovation by simplifying the adoption of digital endpoints.”
About the 2021 Deloitte Technology Fast 500™
Now in its 27th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2017 to 2020.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
Clinical Ink ranked No. 393 on the Deloitte Technology Fast 500 ™.
About Clinical Ink
Clinical Ink , a global clinical technology company, offers data certainty from source to submission. Our Lunexis™ eSource clinical technology and configurable direct data capture, eCOA, patient engagement, telehealth, eConsent, and instrumented data collection modules provide a suite of solutions for capturing and integrating electronic data from sites, clinicians, caregivers, and patients at its source. Clinical Ink’s therapeutic-area-specific approach to study design and data capture – with specific expertise in neurocognitive testing – enables more precise scales for cognitive and human factors assessments, including performance, behavior, movement, and all real-world activity.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006158/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates1.10.2026 10:30:00 CEST | Press release
The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4 additional assetsThe partnership will cover development and commercialization in the United States, Europe, and Canada, with an option to expand to other territoriesThe partnership brings together Samsung Bioepis’ development, regulatory and manufacturing capabilities with Teva’s global commercial reach to advance the investigational biosimilar candidates and help bring additional important treatment options to patients worldwide Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizum
FPT and ZEBOX Partner to Advance AI and Sustainable Innovation in Logistics1.10.2026 10:00:00 CEST | Press release
FPT, a global technology and IT services provider, and ZEBOX, the international innovation accelerator initiated by the CMA CGM Group, have entered into a three-year strategic partnership to develop and deploy AI-powered solutions for the transport and logistics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001622214/en/ The partnership was formalized during the Vietnam - France Leaders Forum, held as part of Vietnam’s General Secretary and State President’s official visit to France. The partnership will combine FPT’s expertise in artificial intelligence, automation and large-scale digital transformation with ZEBOX’s innovation network and its close connection to the CMA CGM Group’s global transport and logistics ecosystem. The partners will focus on shipping, port operations, logistics, supply chain management and clean energy. A first joint initiative in Vietnam As a first step, FPT, ZEBOX and CMA CGM Vietnam
Telekom Srbija (Group) Is Building City-Scale Digital Infrastructure for EXPO 20271.10.2026 10:00:00 CEST | Press release
On a site that will function, in terms of capacity, as an entirely new urban district, with more than 46 kilometres of fibre-optic network, 35 radio sites, 5G Standalone and Wi-Fi 7, Telekom Srbija Group is presenting the digital ecosystem it is building for over 135 participating countries and four million expected visitors. Telekom Srbija sees EXPO 2027 as a platform for strengthening its global positioning and marketing its products and services. Telekom Srbija Group is building telecommunications infrastructure at the EXPO 2027 Belgrade site whose mobile segment is comparable in scale to that of an entire urban district. On a site that previously had no telecommunications infrastructure, more than 14 kilometres of telecommunications ducting and over 46 kilometres of high-capacity fibre-optic network have been delivered so far, together with 35 advanced radio access network sites. The digital ecosystem, based on 5G Standalone and Wi-Fi 7 technologies, is designed to provide reliable
ROYC Group Launches ROYC Operating System as a Standalone Enterprise Software Platform1.10.2026 09:30:00 CEST | Press release
ROYC Group today announced the launch of ROYC Operating System (ROYC OS) as a standalone software platform for fund managers, banks and wealth managers across private markets. The software is now available separately from ROYC’s existing structuring, fund operations and distribution services. Proven in production, at scale ROYC used its structuring and fund operations experience to develop its enterprise-grade digital offering that automates these services. The technology has been live in production for years, bundled with ROYC's services with more than 20 fund managers operating drawdown and evergreen funds on the ROYC OS, distributing to over 50 banks and wealth managers. “We saw where legacy solutions were failing fund managers: spreadsheets and software assembled from separate tools bolted together over time, with no single record connecting a fund to its service providers and investors,” said Octavian Popescu, Co-Founder and CEO of ROYC Group. “We built ROYC OS the other way aroun
Eaton Strengthens European Manufacturing With Expanded Production Facility in Austria1.10.2026 09:00:00 CEST | Press release
Increased capacity supports growing demand from electrification and critical infrastructure marketsNew fully automated miniature circuit breaker production and expanded low-voltage systems assembly capacity in Schrems5,000 m² facility expansion combines advanced automation, digital integration and end-to-end product traceability Eaton will celebrate the expansion of its manufacturing facility in Schrems, Austria, on 1 October 2026. The expansion supports growing demand driven by electrification and digitalisation across Europe while increasing regional manufacturing capacity for electrical protection and power management solutions. Completed in less than ten months, the expansion combines fully automated production with advanced digital integration and end-to-end product traceability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001416101/en/ Eaton expanded manufacturing capacity in Europe for power management solutions
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom